Hematologic Oncology

CAR T-cell therapies are associated with a risk for second primary cancers, and mitigation strategies for these toxic effects are warranted and under examination.

Peter Riedell, MD, details the safety and efficacy of rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Alan Skarbnik discusses interim findings from the Phase 3 AMPLIFY trial, highlighting the efficacy and safety of fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, compared to chemoimmunotherapy for treatment-naive chronic lymphocytic leukemia.

Ashkan Emadi, MD, PhD, discusses early efficacy signals with venetoclax plus pegcrisantaspase in relapsed/refractory AML.

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, highlight key data in CML and ALL presented at the 2024 ASH Annual Meeting.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, detail factors for selecting a TKI in later lines of therapy in chronic myeloid leukemia.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss data for ponatinib plus chemotherapy in Ph-positive ALL.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss dosing strategies for ponatinib in CML and ALL.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the mutational analysis for ponatinib in the OPTIC trial in CP-CML.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss 5-year data for ponatinib in pretreated CP-CML.

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

Naval G. Daver, MD, discusses the potential role for menin inhibitors in the frontline treatment of patients with acute myeloid leukemia.

The FDA issued a CRL to the BLA of tabelecleucel in EBV+ PTLD following at least 1 prior line of treatment.

Naseema Gangat, MBBS, discusses the role of rusfertide for decreasing phlebotomy needs and the potential future for disease-modifying PV management.

Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

Ann S. LaCasce, MD, MMSc, discusses updates in the Hodgkin lymphoma treatment paradigm.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.

Daniel DeAngelo, MD, PhD, discusses the effect of avapritinib on bone density in patients with advanced systemic mastocytosis.

Armin Ghobadi, MD, discusses the safety profile of WT-7 in heavily pretreated relapsed/refractory T-ALL and LBL.

Ashkan Emadi, MD, PhD, discusses responses achieved with venetoclax plus PegC in patients with venetoclax-pretreated, relapsed/refractory AML.